文献速递肝病消化道肿瘤与早癌

酒精相关肝细胞癌的全球患病率、临床特征、监测、治疗分配与结局

Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular Carcinoma.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-07-08

该系统综述与Meta分析检索Medline和Embase至2023年1月,纳入55篇文章共86,345例患者,发现30.4%的肝细胞癌为酒精相关;酒精相关肝细胞癌监测率较低(20.8%),BCLC 0/A期可能性较低(OR 0.7),接受治愈性治疗可能性较低(24.5% vs 33.9%;OR 0.7),死亡率较高(HR 1.3)。

要点

  • 30.4%的肝细胞癌为酒精相关,欧洲比例最高、美洲最低。
  • 酒精相关肝细胞癌监测率20.8%,低于乙肝、丙肝和代谢功能障碍相关肝细胞癌。
  • 酒精相关肝细胞癌BCLC 0/A期可能性较低(OR 0.7),治愈性治疗率24.5% vs 33.9%(OR 0.7),死亡率较高(HR 1.3)。

核心结论

  • 酒精相关肝细胞癌与较低的监测率、更晚的BCLC分期、较低的治愈性治疗可能性及较差的生存相关。
  • 作者认为这些数据呼吁采取措施减少重度饮酒并改善高危个体的有效肝细胞癌监测策略。

研究设计与样本

  • 系统综述与Meta分析,检索Medline和Embase自建库至2023年1月。
  • 共纳入55篇文章,86,345例患者。
  • 比例数据采用广义线性混合模型分析,采用配对Meta分析获得比值比(OR)或均数差,生存结局采用风险比合并分析。

主要发现

  • 30.4%(95%CI 24.0%-37.7%)的肝细胞癌为酒精相关,欧洲比例最高、美洲最低。
  • 酒精相关肝细胞癌患者更多为男性,但年龄和合并症与其他病因相似。
  • 酒精相关肝细胞癌监测率为20.8%(95%CI 11.4%-34.9%),乙肝、丙肝和代谢功能障碍相关肝细胞癌分别为35.0%、31.6%和21.4%(所有P < .05)。
  • 与其他病因相比,酒精相关肝细胞癌BCLC 0/A期可能性较低(OR 0.7;95%CI 0.6-0.9;P = .018),接受治愈性治疗可能性较低(24.5% vs 33.9%;OR 0.7;95%CI 0.5-0.9;P = .003),死亡率较高(HR 1.3;95%CI 1.1-1.5;P = .012)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although the burden of alcohol-associated hepatocellular carcinoma (HCC) is increasing with rising alcohol consumption, clinical presentation and outcomes of alcohol-associated HCC have not been systematically assessed. We aimed to determine the prevalence, clinical characteristics, surveillance rates, treatment allocation, and outcomes of alcohol-associated HCC. METHODS: Medline and Embase were searched from inception to January 2023. Proportional data were analyzed using a generalized linear mixed model. The odds ratio (OR) or mean difference comparing alcohol-associated HCC and other causes was obtained with pairwise meta-analysis. Survival outcomes were evaluated using a pooled analysis of hazard ratios. RESULTS: Of 4824 records identified, 55 articles (86,345 patients) were included. Overall, 30.4% (95% confidence interval [CI], 24.0%-37.7%) of HCC was alcohol associated, with the highest proportion in Europe and the lowest in the Americas. People with alcohol-associated HCC were more likely male but were similar in age and comorbidities compared with other causes. A total of 20.8% (95% CI, 11.4%-34.9%) of people with alcohol-associated HCC underwent surveillance compared with 35.0%, 31.6%, and 21.4% in hepatitis B virus, hepatitis C virus, and metabolic dysfunction-associated HCC, respectively (all P < .05). Alcohol-associated HCC had a lower likelihood of Barcelona Clínic Liver Cancer C stage (0/A) (OR, 0.7; 95% CI, 0.6-0.9; P = .018) and curative therapy (24.5% vs 33.9%; OR, 0.7; 95% CI, 0.5-0.9; P = .003), and higher mortality (HR, 1.3; 95% CI, 1.1-1.5; P = .012) when compared with other causes. CONCLUSIONS: Alcohol-associated HCC is associated with lower surveillance rates, more advanced BCLC stage, lower likelihood of receiving curative therapy, and poorer survival. These data call for measures to reduce heavy alcohol consumption and improve strategies for effective HCC surveillance in high-risk individuals.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Zeng RW, Ong CEY, Ong EYH, et al. Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2024. PMID: 38987014. doi:10.1016/j.cgh.2024.06.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。